Literature DB >> 16826477

Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.

Ruchi Singh1, Dhiraj Kumar, Venkatesh Ramesh, Narender S Negi, Surendra Singh, Poonam Salotra.   

Abstract

Individuals with visceral leishmaniasis, or kala azar (KA) and individuals with post-KA dermal leishmaniasis (PKDL) are considered to be reservoirs of transmission of Leishmania donovani in India. When intracellular amastigotes were used to assess the natural susceptibility that PKDL isolates and KA isolates have to sodium antimony gluconate (SAG), the mean ED(50) was found to be 12.0+/-2.49 and 11.0+/-1.38 microg/mL, respectively; and there was a significant correlation with the clinical response (r rank=0.99). All KA isolates, as well as a significant proportion (55%) of PKDL isolates from high-endemicity zones, were resistant to SAG. The median ED(50) for SAG-resistant PKDL isolates (20.0 microg/mL) was significantly higher (P<.05) than that for SAG-resistant KA isolates (15.7 microg/mL). SAG-resistant PKDL isolates may contribute to KA's increased refractoriness to SAG, via anthroponotic transmission of SAG-resistant strains.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16826477     DOI: 10.1086/505079

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Authors:  Dhiraj Kumar; Ruchi Singh; Vasundhra Bhandari; Arpita Kulshrestha; Narendra Singh Negi; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

2.  In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

Authors:  Dhiraj Kumar; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.

Authors:  Arpita Kulshrestha; Vasundhra Bhandari; Rupkatha Mukhopadhyay; V Ramesh; Shyam Sundar; Louis Maes; Jean Claude Dujardin; Syamal Roy; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-12-13       Impact factor: 2.289

4.  Transmission potential of antimony-resistant leishmania field isolates.

Authors:  Veronika Seblova; Bruno Oury; Naouel Eddaikra; Khatima Aït-Oudhia; Francine Pratlong; Elodie Gazanion; Carla Maia; Petr Volf; Denis Sereno
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

5.  Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.

Authors:  Arpita Kulshrestha; Ruchi Singh; Dhiraj Kumar; Narender Singh Negi; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

6.  Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.

Authors:  B V Subba Raju; Srividya Gurumurthy; Katrin Kuhls; Vasundhra Bhandari; Gabriele Schnonian; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07-01       Impact factor: 2.289

7.  Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation.

Authors:  Arun Kumar Haldar; Vinod Yadav; Eshu Singhal; Kamlesh Kumar Bisht; Alpana Singh; Suniti Bhaumik; Rajatava Basu; Pradip Sen; Syamal Roy
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

8.  Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis.

Authors:  N A Ansari; G K Katara; V Ramesh; P Salotra
Journal:  Clin Exp Immunol       Date:  2008-12       Impact factor: 4.330

Review 9.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01

10.  Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan.

Authors:  A M Musa; E A G Khalil; B M Younis; M E E Elfaki; M Y Elamin; A O A Adam; H A A Mohamed; M M M Dafalla; A A Abuzaid; A M El-Hassan
Journal:  J Trop Med       Date:  2013-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.